- MeSH
- Histones biosynthesis MeSH
- Enzyme Inhibitors administration & dosage therapeutic use MeSH
- Humans MeSH
- DNA Methylation MeSH
- Myelodysplastic Syndromes * diagnosis drug therapy pathology therapy MeSH
- Nucleosides administration & dosage therapeutic use MeSH
- Antimetabolites, Antineoplastic * administration & dosage therapeutic use MeSH
- Triazines administration & dosage therapeutic use MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
V roce 2011 dojde k zásadní změně v léčbě chronické infekce virem hepatitidy C (HCV). Příčinou této změny je komerční dostupnost nových antivirových léků pro terapii chronické infekce HCV – telapreviru a bocepreviru – v kombinaci s pegylovaným interferonem (PEG-IFN) alfa a ribavirinem. Schválení těchto léků lze očekávat ve Spojených státech a Evropské unii pravděpodobně v červnu 2011. Jak u pacientů dosud antivirově neléčených, naivních, tak u nemocných, u kterých klasická léčba PEG-IFN a ribavirinem nevedla k trvalé eliminaci infekce HCV, je trojkombinační léčba významně účinnější než kombinace PEG-IFN a ribavirinu.
In 2011, there will be a major change in the treatment of chronic infection with hepatitis C virus (HCV). The reason for this change is the commercial availability of novel antiviral drugs for the treatment of chronic HCV infection – telaprevir and boceprevir – in combination with pegylated interferon (PEG-IFN) alpha and ribavirin. These drugs are likely to be approved in the United States and the European Union in june 2011. In patients not yet treated with antiviral drugs (treatment-naive ones) as well as in those in whom classical treatment with PEG-IFN and ribavirin failed to eliminate HCV infection permanently, the triple combination therapy is significantly more effective than the combination of PEG-IFN and ribavirin. boceprevir, telaprevir.
- Keywords
- pegylovaný interferon alfa, konvenční interferon alfa, adefovir dipivoxil, entecavir, boceprevir, telaprevir,
- MeSH
- Adenine analogs & derivatives adverse effects therapeutic use MeSH
- Antiviral Agents therapeutic use MeSH
- Hepatitis, Chronic MeSH
- Drug Therapy methods utilization MeSH
- Guanine analogs & derivatives administration & dosage therapeutic use MeSH
- Interferon-alpha administration & dosage adverse effects therapeutic use MeSH
- Interferons administration & dosage adverse effects therapeutic use MeSH
- Lamivudine analogs & derivatives administration & dosage therapeutic use MeSH
- Humans MeSH
- Nucleosides administration & dosage adverse effects therapeutic use MeSH
- Oligopeptides administration & dosage adverse effects therapeutic use MeSH
- Proline analogs & derivatives administration & dosage therapeutic use MeSH
- Pyrimidinones administration & dosage adverse effects therapeutic use MeSH
- Ribavirin administration & dosage adverse effects therapeutic use MeSH
- Statistics as Topic MeSH
- Telbivudine MeSH
- Tenofovir MeSH
- Hepatitis, Viral, Human drug therapy immunology therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
Jsou uvedeny nové poznatky v epidemiologii chronické infekce HBV, je zhodnocen význam sérokonverze HBeAg pro správnou indikaci léčby antivirotiky a zdůrazněn význam nízkých hodnot virémie po skončení léčby jako hlavní cíl protivirové léčby společně s velmi nízkou aktivitou ALT v dolní polovině normálních hodnot, což má rozhodující význam pro prevenci jaterní cirhózy a hepatocelulárního karcinomu. Zcela recentní je informace o účinnosti a bezpečnosti tenofovir disoproxil fumarátu při porovnání s adefovir dipivoxilem.
In this article new knowledge of the epidemiology of chronic HBV infection is introduced and the importance of HBeAg seroconversion for correct indication of antiviral treatment is assessed. Further the importance of low viraemia at end of treatment as a main goal of antiviral therapy along with a very low ALT activity in the lower half of normal values, which is crucial for the prevention of liver cirrhosis and hepatocellular carcinoma, is stressed. Quite recent is information on the efficacy and safety of tenofovir disoproxil fumarate when compared with adefovir dipivoxil.
- MeSH
- Adenine analogs & derivatives pharmacology therapeutic use MeSH
- Hepatitis B, Chronic epidemiology drug therapy therapy MeSH
- Hepatitis B e Antigens analysis blood drug effects MeSH
- Humans MeSH
- Drug-Related Side Effects and Adverse Reactions MeSH
- Nucleosides administration & dosage pharmacology therapeutic use MeSH
- Organophosphonates administration & dosage pharmacology therapeutic use MeSH
- Pyrimidinones administration & dosage pharmacology therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
Vzhledem k prakticky identické epidemiologii vyvolávajících agens, je u HIV pozitivních osob velmi častá koinfekce s viry hepatitidy C nebo B. Virem hepatitidy C je infikováno kolem 30 % HIV pozitivních pacientů a známky prodělané infekce VHB má v některých souborech až 90 % HIV pozitivních pacientů. Koinfekce s HIV znamená rychlejší progresi jaterního onemocnění jak při hepatitidě C, tak i B, naopak přítomnost infekce HCV nebo HBV zásadně neovlivňuje průběh nemoci HIV. V léčbě virové hepatitidy C u HIV koinfikovaných osob je zlatým standardem kombinace pegylovaného interferonu a ribavirinu. V léčbě chronické virové hepatitidy B se uplatňují interferony a nukleosidové analogy, které mají často duální protivirovou aktivitu s účinkem na virus HIV i HBV. Průběh infekce virem hepatitidy A není u HIV pozitivních osob modifikován. Určitý benefit na průběh HIV infekce byl zaznamenán u HIV/HGV koinfekce.
The co-infection of HIV and HCV or HBV is very common since all these agents share a very similar epidemiology. Approximately 30 % of all HIV positive patients are co-infected with HCV and in some cohorts up to 90 % of HIV positive patients have markers of HBV infection. Co-infection with HIV leads to the more rapid progression of both hepatitis C and B, but the presence of either HCV or HBV does not substantially influence the course of the HIV infection. The combination of pegylated interferon and ribavirin is the gold standard for therapy of HIV/HCV co-infected patients. Interferons and nucleoside analogues are used in the treatment of chronic hepatitis B, which often have dual antiviral activity against HIV and HBV. The course of hepatitis A is not modified in HIV positive patients. Co-infection with hepatitis G has been demonstrated to have some positive effect on the course of the HIV infection.
- MeSH
- Epidemiologic Studies MeSH
- Drug Therapy methods MeSH
- Research Support as Topic MeSH
- Hepatitis A complications prevention & control MeSH
- Hepatitis B drug therapy complications therapy MeSH
- Hepatitis C drug therapy complications therapy MeSH
- Hepatitis D complications MeSH
- HIV Infections complications MeSH
- Interferon-alpha administration & dosage therapeutic use MeSH
- Humans MeSH
- Liver Diseases etiology classification therapy MeSH
- Nucleosides administration & dosage therapeutic use MeSH
- Primary Prevention methods MeSH
- Ribavirin administration & dosage therapeutic use MeSH
- GB virus C immunology pathogenicity MeSH
- Check Tag
- Humans MeSH
- MeSH
- Adenine analogs & derivatives administration & dosage therapeutic use MeSH
- Hepatitis B, Chronic drug therapy complications MeSH
- Child MeSH
- Adult MeSH
- Guanine analogs & derivatives administration & dosage therapeutic use MeSH
- Interferon-alpha administration & dosage therapeutic use administration & dosage therapeutic use MeSH
- Liver Cirrhosis drug therapy MeSH
- Lamivudine administration & dosage therapeutic use MeSH
- Humans MeSH
- Nucleosides administration & dosage therapeutic use MeSH
- Organophosphonates administration & dosage therapeutic use MeSH
- Pyrimidinones administration & dosage therapeutic use MeSH
- Severity of Illness Index MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Publication type
- Practice Guideline MeSH
- Keywords
- GEMCITABINE (ELI LILLY),
- MeSH
- Deoxycytidine analogs & derivatives MeSH
- Humans MeSH
- Survival Rate MeSH
- Carcinoma, Non-Small-Cell Lung drug therapy MeSH
- Nucleosides administration & dosage therapeutic use MeSH
- Signs and Symptoms drug therapy MeSH
- Antineoplastic Agents administration & dosage pharmacology MeSH
- Check Tag
- Humans MeSH
